Respiratory Syncytial Virus (RSV) Therapeutics Market size was valued at USD 1.85 Billion in 2024 and is projected to reach USD 5.12 Billion by 2033, exhibiting a CAGR of 15.2% from 2026 to 2033.
The European Respiratory Syncytial Virus (RSV) therapeutics market is experiencing significant growth, driven by innovative treatments and strategic market dynamics. In August 2024, the European Commission approved mResvia, a messenger RNA (mRNA) vaccine developed by Moderna, marking the first non-COVID-19 mRNA vaccine approved in Europe. This vaccine demonstrated an 83.7% efficacy rate in preventing lower respiratory tract diseases caused by RSV among seniors aged 60 and above. citeturn0news12 The market is predominantly led by monoclonal antibodies, with palivizumab being the most recognized. In 2023, palivizumab accounted for a substantial portion of the market share, attributed to its efficacy in preventing severe RSV infections in high-risk populations, including premature infants and those with chronic health conditions. citeturn0search1 Distribution channels play a crucial role in the accessibility of RSV therapeutics. Hospital pharmacies are the primary distributors, owing to their capacity to manage specialized medications and provide patient monitoring. In 2023, hospital pharmacies held a significant market share, with expectations of continued growth through 2032. citeturn0search1 Geographically, Germany exhibits substantial growth potential in the RSV therapeutics market. The country's robust research and development infrastructure, coupled with government support, positions it as a leader in RSV therapeutic advancements. citeturn0search1 Recent developments highlight the competitive landscape of RSV vaccines. GSK's RSV vaccine, Arexvy, achieved over $1 billion in sales but faced scrutiny over its high cost and rare side effects, leading to reduced demand. This scenario underscores the need for cost-effective and user-friendly vaccine solutions. citeturn0news14 In October 2024, the World Health Organization recommended vaccinating pregnant women and administering antibody shots to infants to prevent severe RSV infections. This guidance aims to reduce the significant morbidity and mortality associated with RSV, particularly among infants and older adults. citeturn0news15 Overall, the European RSV therapeutics market is evolving with advancements in vaccine technology, strategic distribution, and comprehensive preventive measures. These developments aim to enhance patient outcomes and address the challenges posed by RSV infections across diverse populations.
Get an In-Depth Research Analysis of the Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size And Forecast [2025-2032]
Roche
AstraZeneca
Merck
AbbVie
Valeant Pharmaceuticals
GlaxoSmithKline
ReViral
Gilead Sciences
Teva Pharmaceutical
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Europe region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Europe Respiratory Syncytial Virus (RSV) Therapeutics Market
Monoclonal Antibodies
Antiviral Drugs
Vaccines
Supportive Care Products
Intravenous (IV)
Subcutaneous (SC)
Inhalation
Oral
Pediatric (Infants and Young Children)
Adult
Elderly
Acute Bronchiolitis
Pneumonia
Chronic Obstructive Pulmonary Disease (COPD)
Immunocompromised Patients
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Clinics
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
For More Information or Query, Visit @ Respiratory Syncytial Virus (RSV) Therapeutics Market Research Analysis
1. Introduction of the Europe Respiratory Syncytial Virus (RSV) Therapeutics Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Market Size And Trends
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, By Type
6. Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, By Application
7. Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, By Geography
Europe
8. Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Market Size And Trends
Market Size And Trends is a leading Europe Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.marketsizeandtrends.com/